Physician profile
Susan Barton
NPI 1235145574
$3,044.04
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $907 · 2020: $516 · 2021: $182 · 2022: $532 · 2023: $596 · 2024: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $906.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $657.97 | 2019-2024 | Xifaxan, Plenvu, Relistor |
| Abbvie INC. | $439.45 | 2019-2024 | Skyrizi, Viberzi, Linzess |
| Genzyme Corporation | $278.42 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $274.18 | 2019-2024 | Entyvio, Gattex |
| Gilead Sciences, INC. | $251.17 | 2019-2020 | |
| Endogastric Solutions, INC | $165.79 | 2019-2020 | |
| Celgene Corporation | $150.87 | 2022-2023 | Zeposia |
| Pfizer INC. | $144.01 | 2019-2024 | |
| Shionogi INC | $112.28 | 2019-2020 | |
| Echosens North America, INC. | $111.94 | 2019 | |
| Ferring Pharmaceuticals INC. | $80.60 | 2019-2023 | Rebyota |
| Janssen Biotech, INC. | $71.82 | 2020-2024 | Stelara |
| Astrazeneca Pharmaceuticals Lp | $53.62 | 2020 | |
| Intercept Pharmaceuticals, INC. | $42.74 | 2020 | |
| Qol Medical, LLC | $24.58 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $24.19 | 2021 | |
| Redhill Biopharma INC. | $23.64 | 2020 | |
| Boston Scientific Corporation | $22.88 | 2023 | Acquire |
| Braintree Laboratories, INC. | $19.81 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $19.25 | 2024 | Dupixent |
| Fresenius Kabi USA, LLC | $18.28 | 2024 | Idacio |
| Digestive Care, INC. | $16.67 | 2021 | |
| Mauna Kea Technologies, INC. | $13.76 | 2023 | |
| Ironwood Pharmaceuticals, INC | $13.24 | 2019 | |
| Allergan, INC. | $12.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Barton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.